Ribociclib With Everolimus And Dexamethasone For Relapsed ALL

AddtoAny
Share:

WATCH THIS PAGE

Subscribe to be notified of changes or updates to this page.

4 + 2 =
Solve this simple math problem and enter the result. E.g. for 1+3, enter 4.

CHOP, in collaboration with Dana-Farber Cancer Institute, is conducting a study for children, adolescents, and young adults up to 31 years old, with relapsed or refractory acute lymphoblastic leukemia. This clinical trial is adding the study drugs ribociclib and everolimus to a standard relapse chemotherapy regimen. For more information about this study, including specific eligibility criteria, please visit clinicaltrials.gov. To hear more about this and other available trails or get any questions answered please contact our Cancer Intake Specialist by phone at 267-426-0762 or email oncointake@chop.edu.

Who Do I Contact?

If you are interested in participating in the study or want to learn more please contact our study team at oncointake [at] chop.edu or 267-426-0762.

Eligibility & Criteria

IRB #:
19-016302
Official Title:
Phase I Trial Of Ribociclib In Combination With Everolimus And Dexamethasone In Children And Young Adults With Relapsed Acute Lymphoblastic Leukemia
Study Phase:
Phase I
Eligible Age Range:
1 - 30 Years
Gender:
All
Study Categories:
Leader
Susan R. Rheingold

Susan R. Rheingold, MD